PeptideStack
5.2kquestions
20kanswers
220users

clinical-trials

Page 27 of 32 · 745 questions tagged clinical-trials.

745 questions · sorted by votes · page 27 of 32

8 votes 5 answers5.9k views
What did the placebo arm of TRIUMPH-3 report for dizziness?

Conditions: TRIUMPH-3 · dizziness. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
asked by ahmed_zerouali 15k · 10 months ago
8 votes0 answers5.7k views
How comparable are survodutide and semaglutide on the evidence available?

Setup, so nobody has to ask: survodutide · semaglutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
asked by syringe_ninety 12k · 20 months ago
8 votes0 answers4.8k views
Is SURMOUNT-4 a fair comparison of tirzepatide against its comparator arm?

Setup, so nobody has to ask: SURMOUNT-4 · tirzepatide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by birk_nordahl 16k · 8 months ago
8 votes2 answers3.5k views
What does STEP 2 report at the 1 mg dose level?

The case in front of me: STEP 2 · 1 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by Dr_Bram_Verhoeven 84k · 4 months ago
8 votes0 answers1.9k views
Is there any published stability data for dulaglutide at 2–8 °C?

What I am working with: dulaglutide · 2–8 °C. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dulaglutide
dulaglutide

A once-weekly GLP-1 receptor agonist built on an Fc fusion rather than fatty-acid acylation. Use this tag for questions about the fusion-protein…

200 questions
asked by ravenna_pace 14k · 38 days ago
7 votes 5 answers17k views
What did the placebo arm of PIONEER-4 report for dizziness?

What I am working with: PIONEER-4 · dizziness. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
asked by forty_two_c 66k · 15 months ago
7 votes 5 answers17k views
How comparable are dulaglutide and mazdutide on the evidence available?

Details up front: dulaglutide · mazdutide. Both of these get recommended confidently by different people, which suggests neither is obviously right. My constraints…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
dulaglutide
dulaglutide

A once-weekly GLP-1 receptor agonist built on an Fc fusion rather than fatty-acid acylation. Use this tag for questions about the fusion-protein…

200 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

237 questions
asked by sample_id 17k · 13 months ago
7 votes 5 answers13k views
Is 0.25 mg weekly a defensible maintenance dose for liraglutide?

The case in front of me: 0.25 mg · liraglutide. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would…

maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

54 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

235 questions
asked by forty_units 16k · 17 months ago
7 votes5 answers12k views
What does STEP 5 report at the 1 mg dose level?

Stated plainly: STEP 5 · 1 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including the method…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by eoin_mcgarry 18k · 16 months ago
7 votes 5 answers9.3k views
What did ESSENCE do with participants who could not tolerate a step?

My records go back to the first dose with dates, so I can reconstruct the timeline exactly. I have read the primary source rather than the summary, which has left me…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by Dr_Tomas_Kral 53k · 5 months ago
7 votes 3 answers5.1k views
What does STEP 4 report at the 1 mg dose level?

Setup, so nobody has to ask: STEP 4 · 1 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by grainne_ahearn 50k · 18 months ago
7 votes0 answers3.2k views
Why do two papers on FLOW report different headline figures?

I have the full paper rather than the abstract, and the supplementary appendix. I would like the mechanism, because I want to be able to reason about the cases nobody…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by v_ramaswamy 68k · 3 months ago
7 votes0 answers2.9k views
Is the maximum studied dose the same as the maximum useful dose?

My records go back to the first dose with dates, so I can reconstruct the timeline exactly. I suspect the honest answer is that it depends, in which case I would like…

maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

54 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dose-escalation
dose-escalation

The decision to move up a step: what evidence supports a four-week interval, what happens when you compress it, and how trial protocols handled…

103 questions
asked by eighty_six_hours 20k · 16 months ago
7 votes0 answers2.8k views
What does SOUL tell me about vomiting at the 7 mg dose?

Stated plainly: SOUL · vomiting · 7 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by bac_or_bust 33k · 16 months ago
7 votes 2 answers2.5k views
What did SURMOUNT-1 do with participants who could not tolerate a step?

I am asking about the protocol logic rather than about my own case specifically. I can parse the result. I am less sure what it licenses me to conclude. I have…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by assay_blank 45k · 2 months ago
7 votes 4 answers2.3k views
What does ATTAIN-1 report at the 12 mg dose level?

Stated plainly: ATTAIN-1 · 12 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do not…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by anders_vestby 8.5k · 2 months ago
7 votes2 answers2.1k views
Is there any published stability data for oral semaglutide at 37 °C?

For reference: oral semaglutide · 37 °C. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I would…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by stopper_core 28k · 17 days ago
7 votes0 answers1.6k views
How would a trial separate a glucagon effect from a weight-loss effect?

I would like to know how much of this is established and how much is a reasonable story. I can find plenty of assertions about this and almost no reasoning, which is…

glucagon-receptor
glucagon-receptor

Glucagon receptor agonism as a deliberate component of dual and tri-agonists: what it adds in energy expenditure and hepatic fat mobilisation, and…

8 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
asked by Dr_Lena_Ostrowska 38k · 4 months ago
7 votes 2 answers1.2k views
Is 2.4 mg weekly a defensible maintenance dose for liraglutide?

Concretely: 2.4 mg · liraglutide. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like the plan to…

maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

54 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

235 questions
asked by colm_dunphy 8.2k · 28 days ago
6 votes 5 answers26k views
What did the placebo arm of TRIUMPH-3 report for constipation?

The particulars: TRIUMPH-3 · constipation. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
asked by swab_and_wait 13k · 2.0 years ago
6 votes 4 answers21k views
What is the reported incidence of reflux on retatrutide in TRIUMPH-1?

The particulars: reflux · retatrutide · TRIUMPH-1. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is…

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by forty_units 16k · 2.1 years ago
6 votes4 answers21k views
Does the ATTAIN-1 population resemble anyone asking about orforglipron here?

What I have: ATTAIN-1 · orforglipron. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by label_claim 30k · 2.2 years ago
6 votes5 answers20k views
What is the reported incidence of injection-site erythema on retatrutide in TRIUMPH-1?

The particulars: injection-site erythema · retatrutide · TRIUMPH-1. I want to understand what this actually establishes, as opposed to what it is being used to imply.…

injection-site-reaction
injection-site-reaction

Local reactions: erythema, induration, pruritus and nodules. Their relationship to injection depth, diluent composition, benzyl alcohol…

49 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by klara_novotna 19k · 18 months ago
6 votes 5 answers19k views
How comparable are tirzepatide and cagrilintide on the evidence available?

Setup, so nobody has to ask: tirzepatide · cagrilintide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
asked by rosa_mendieta 8k · 20 months ago